Home › Trials › NCT06122779

Evaluating a new treatment for heart failure with preserved ejection fraction

A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Phase 2 Interventional Bristol-Myers Squibb · NCT06122779

This study is testing a new drug to see if it can safely help adults with heart failure and preserved ejection fraction feel better.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment208 (estimated)
Ages40 Years to 85 Years
SexAll
SponsorBristol-Myers Squibb Industry-sponsored
Locations117 sites (Birmingham, Alabama and 116 other locations)
Trial IDNCT06122779 on ClinicalTrials.gov

What this trial studies

This study aims to assess the safety and tolerability of the drug BMS-986435/MYK-224 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF). Participants will receive either the active drug or a placebo, and the study will monitor drug levels and the body's response to the treatment. The goal is to determine how well the drug is tolerated and its potential effectiveness in managing HFpEF symptoms.

Who should consider this trial

Good fit: Ideal candidates are adults with stable, symptomatic heart failure with preserved ejection fraction and normal heart pumping ability.

Not a fit: Patients with obstructive or genetic hypertrophic cardiomyopathy, infiltrative/storage disorders, or other serious conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve the management of heart failure with preserved ejection fraction, enhancing patients' quality of life.

How similar studies have performed: Other studies have explored treatments for heart failure, but the specific approach of this trial is novel and untested.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

\- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.

Exclusion Criteria

* Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

Birmingham, Alabama and 116 other locations

+67 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Heart FailureBMS-986435MYK-224PharmacokineticsPharmacodynamicsSafetyHFpEF
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.